A focused 90-day pilot to prove how Ario can turn fragmented real-world data into strategic advantage.
Our pilot program is designed for selected life sciences customers who want to evaluate a high-value use case before broader adoption. It gives teams a practical way to test Ario on a real strategic question and measure the business value of faster, more connected insight.
Start with one critical question. End with a clearer path forward.
Think of the program like a strategic MRI for your data. Instead of running broad, slow analyses across disconnected tools, we focus the pilot on a specific business question and use Ario to reveal the signals, pathways, and opportunities that matter most.
Over 90 days, selected customers can validate whether Ario can accelerate decision-making, improve evidence clarity, and uncover expansion opportunities hidden in complex real-world data.
Designed for selected teams that need sharper evidence, faster.
We are prioritizing customers where a focused pilot can create immediate strategic value and establish a clear path to broader adoption.
Emerging biopharma teams
For companies that need strategic-grade insight without waiting to build a large internal AI, data science, and RWE stack.
Medical Affairs and RWE leaders
For teams evaluating label expansion hypotheses, responder populations, and off-label patterns with stronger traceability and speed.
Cross-functional launch and planning teams
For organizations that need one shared view across R&D, regulatory, medical, and commercial stakeholders.
A 90-day path from proof-of-value to enterprise-scale impact.
The pilot is structured in four phases so teams can move from alignment to evidence to executive decision-making within a single quarter.
Weeks 1–2: Align on the strategic question
Select one high-value use case, define success metrics, identify decision stakeholders, and align on the evidence needed to inform action.
Weeks 2–4: Unify data and scope analysis
Connect the relevant real-world data inputs, validate cohort logic, and structure the analysis plan around the pilot objective.
Weeks 5–8: Generate findings and quantify opportunity
Surface treatment patterns, responder segments, and expansion signals, then translate them into quantified market and strategic implications.
Weeks 9–12: Deliver outputs and define scale-up
Review results with stakeholders, produce decision-grade outputs, and map the strongest next use cases for broader deployment.
What selected customers should expect to leave with.
By the end of the 90-day pilot, the goal is to provide more than analysis. The engagement is designed to give leadership a concrete set of outputs they can use to decide what to prioritize next.
Prove value before committing to a broader rollout.
Most organizations do not need another abstract AI demo. They need confidence that a new platform can improve a live strategic decision. This pilot program is built to create that confidence.
90-day proof of value
A time-boxed program to evaluate Ario against a live strategic question without a broad, open-ended rollout.
Built for life sciences
Designed around real-world evidence, patient journeys, semantic normalization, and label expansion strategy.
Decision-oriented
The goal is not just analytics. The goal is to produce evidence that supports prioritization, investment, and action.
Expansion-ready
Successful pilots create a practical foundation for broader deployment across functions, datasets, and assets.
A foundation for broader enterprise value.
Once a pilot demonstrates value, Ario can expand into broader workflows across R&D, regulatory, medical affairs, HEOR, market access, and commercial strategy. That means one platform, one evidence spine, and fewer handoff gaps between teams.
Interested in being considered?
We are opening the pilot program to a limited number of selected customers where there is strong alignment on the strategic use case, data readiness, and potential value creation. If your team is exploring label expansion, off-label opportunity tracking, or patient population discovery, this may be a strong fit.